571 Results (Page 16 of 23)
UK Markets Research Reports
UK Multiple Sclerosis Drugs Market Analysis
UK Multiple Sclerosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Multiple sclerosis is rising due to increase in Incidence and prevalence of multiple sclerosis (MS), Improved diagnosis and awareness, advancements in healthcare infrastructure , Advancements in Treatment Options, Expanding Pipeline of Innovative Therapies, technological advancements and increase in funding for research of multiple sclerosis. Major global players in Multiple Sclerosis Drugs Market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)
UK Myasthenia Gravis Drugs Market Analysis
UK Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis
UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
UK Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
UK Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
UK POMC Genetic Obesity Drugs Market Analysis
UK POMC Genetic Obesity Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for POMC Genetic Obesity Drugs is growing due to increase spending in research and development activities by pharmaceutical companies, introduction of new emerging therapies like gene editing and gene replacement approaches, incentives provided by regulatory body?s in the form of orphan drug designations. Novo Nordisk A/S , rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated ,Amgen Inc are the key market players operating in global POMC genetic obesity drugs market.
UK Pompe Disease Drugs Market Analysis
UK Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.
UK Primary Hyperoxaluria (PH) Drugs Market Analysis
UK Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
UK Pyruvate Kinase (PK) Deficiency Market Analysis
UK Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.
UK Rare Hematology Disorders Market Analysis
UK Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.
UK Rare Hemophilia Factors Market Analysis
UK Rare Hemophilia Factors market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hemophilia Factors is growing rapidly as a result of growing incidence of rare hemophilia factors deficiency, rising adoption of prophylactic treatments, growing awareness about rare hemophilia factors and their treatment options, rising demand for better and more effective therapies for rare hemophilia factors. Baxter, Bayer AG, Bio Products Laboratory Ltd., Novo Nordisk A/S, Alexion Pharmaceuticals, Amgen Inc, BioMarin, Amgen Inc are the key global market players operating in rare hemophilia factors market.
UK Rett Syndrome Drugs Market Analysis
UK Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
UK Sickle Cell Disease Drugs Market Analysis
UK Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.
UK Soft Tissue Sarcoma Market Analysis
UK Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.
UK Wilson's Disease Drugs Market Analysis
UK Wilson?s Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Drugs is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques , increase in awareness about the disease due to patient advocacy programmes , support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd. , Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in wilson?s disease drugs market.
UK X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis
UK X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.
UK HIV Therapeutics Market Analysis
By 2030, it is anticipated that the UK HIV therapeutics market will reach a value of $378.29 Mn from $357.76 Mn in 2022, growing at a CAGR of 0.7% during 2022-30. The market is primarily dominated by local players such as AstraZeneca, ViiV Healthcare, and British Biologicals. The market is driven by innovation in research and development, increasing awareness campaigns, and government funding policies. The HIV therapeutics market in the UK is segmented by type, product, geography, end user, and distribution channel.
UK Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
The UK Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $475 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022-30 and will reach $706 Mn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate and government initiative. The market is segmented by Drug class and By distribution channel. Some key players in this market are Verona Pharma, GlaxoSmithKline, AstraZeneca, Chiesi, Boehringer Ingelheim, Teva Pharmaceuticals, Novartis, Pfizer, Merck, and others.
UK Interventional Radiology Market Analysis
UK Interventional Radiology Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Interventional Radiology is expanding as a result of the increasing prevalence of chronic diseases which is rising the need for high-quality scans, x-rays, and other radiology procedures. This demand is fueling the development of better instruments and radiology procedures for the early detection and accurate diagnosis of chronic diseases and other disorders as well. Some of the key players in the Interventional Radiology Market include GE Healthcare (US), Koninklijke Philips N.V., Carestream Health, ESAOTE SPA, Hitachi, Ltd., Hologic, Inc., Shimadzu Corporation, Siemens Healthcare GmbH, Canon Medical Systems Corporation, Samsung Medison Co., Ltd., Medtronic, Agfa-Gevaert Group, Teleflex Incorporated, Cook, Analogic Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, and Trivitron Healthcare.
UK Kidney Cancer Diagnostic Market Analysis
UK Kidney Cancer Diagnostic Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Kidney Cancer diagnostics is expanding as a result of the increasing incidence of kidney cancer and rising research and development funding in both developed and developing nations. This demand is fueling the development of better diagnostic tools and methods for the early detection and accurate diagnosis of kidney cancer. Some of the key players in the global kidney cancer Diagnostics Market include Siemens Healthcare Gmbh, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., Canon Medical Systems Corporation, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, and Centogene N.V.
UK Laboratory Information System Market Analysis
UK Laboratory Information System Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Laboratory Information Systems is expanding due to the increasing adoption of electronic systems and the need for efficient healthcare data in both developed and developing nations. This demand is fueling the development of better software and methods for Laboratory Information Systems. Some of the key players in the global Laboratory Information System Market include Thermo Fisher Scientific, Inc.; Siemens; LabVantage Solutions, Inc.; LabWare; Autoscribe Informatics; Illumina, Inc.; Labworks; LabLynx, Inc.; and Accelerated Technology Laboratories, Inc.
UK Liquid Biopsy Market Analysis
UK Liquid Biopsy Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Liquid Biopsy is expanding as a result of rising healthcare spending in both developed and developing nations. This demand is fueling the development of better medical instruments and methods for the accurate diagnosis and treatment of various medical conditions, including cancer. Some of the key players in the global Liquid Biopsy Market include Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic Health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, Mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., Cardiff Oncology, INC., PathAI, Streck, Menarini Silicon Biosystems, and Biocept, Inc.
UK Medical Billing Outsourcing Market Analysis
UK Medical Billing Outsourcing Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The Medical Billing Outsourcing market is expanding due to increasing complexity in healthcare reimbursement and technological advancements in both developed and developing nations. This demand is fueling the requirement for efficient medical billing. Some of the key players in the global Medical Billing Outsourcing Market include Accretive Health, American Medical Collection Agency, BDO USA LLP, CPSI, eClinicalWorks, Healthcare Management Systems, NextGen Healthcare Information Systems, Practice Fusion, Quality Systems, Inc., and Revenue Cycle Partners.
UK Medical Fiber Optics Market Analysis
UK Medical Fiber Optics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Medical Fiber Optics is expanding as a result of the rising prevalence of chronic diseases and increasing demand for minimally invasive surgeries in both developed and developing nations. This demand is fueling the development of better medical fiber optics devices and methods for accurately diagnosing and treating various medical conditions. Some of the key players in the global Medical Fiber Optics Market include Integra Lifesciences Corporation; Fiberoptics Technology Incorporated (FTI); AFL; Coherent, Inc.; Timbercon, Inc.; Gulf Fiberoptics; LEONI, Newport Corporation; SCHOTT; Amphenol Corporation; LEMO, and Hirose Electric Co. Ltd.
UK Medical Tourism Market Analysis
UK Medical Tourism Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Medical Tourism is expanding as a result of advanced medical technologies and comparatively lower costs of treatment in developing countries than in developed countries. Advancements in medical technology and high-quality treatment facilities are also driving the growth of the Medical Tourism market globally. Some of the key players in the medical tourism Market include Apollo Hospitals (India), Bumrungrad International Hospital (Thailand), Bangkok Hospital (Thailand), Fortis Healthcare (India), KPJ Healthcare Berhad (Malaysia), Asklepios Kliniken GmbH (Germany), Anadolu Medical Center (Turkey), Gleneagles Hospital (Singapore), Wooridul Spine Hospital (South Korea), Clemenceau Medical Center (Lebanon).
UK Medication Adherence Market Analysis
UK Medication Adherence Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Medication Adherence is expanding as a result of increasing demand for mHealth technologies and increasing prevalence of chronic diseases in both developed and developing nations. This demand is fueling the development of better software and methods for medication adherence. Some of the key players in the global medication adherence Market include Koninklijke Philips N.V., Cardinal Health Inc., Omnicell Inc., McKesson Corporation, Johnson & Johnson Services, Inc., Proteus Digital Health, Inc., AdhereTech Inc., Qualcomm Incorporated, Adherence Solutions LLC and SMRxT Inc.
